Ecnoglutide
TL;DR
World’s first approved cAMP-biased GLP-1 receptor agonist (China NMPA: T2DM Jan 2026, obesity Mar 2026). Selectively hyperactivates Gαs→cAMP while nearly eliminating β-arrestin-driven receptor internalization → no tachyphylaxis, no plateau. SLIMMER trial: 15.4% mean weight loss at 2.4 mg vs ~12% for semaglutide in same demographic; patients still losing at week 48. Single-receptor mechanism essentially matches Retatrutide’s weight loss despite targeting only GLP-1R — suggesting bias at GLP-1R may be the true active ingredient. Primary integration concern: lean mass loss (25–40% of weight lost may be muscle); pair with XW4475 or SLU-PP-332.
Key Facts
| Status | RX Approved — China NMPA (T2DM Jan 30 2026; obesity Mar 6 2026); not yet US/EU approved |
| Brand names | Xianyida (T2DM) · Xianweiying / Severwin (obesity) |
| Class | cAMP-biased GLP-1RA — cyclic peptide, once-weekly SubQ |
| Mechanism | Gαs→cAMP hyperactivation + markedly reduced β-arrestin → receptors stay surface-expressed → no tachyphylaxis |
| Dosing | 0.6–2.4 mg SubQ weekly; slow titration (escalate by 0.6 mg increments to limit GI effects) |
| Key risk | Lean mass loss — 25–40% of weight lost may be muscle; mitigate with XW4475, protein, resistance training |
| Evidence | Phase 3: EECOH-1/2 (Nature Comms / Lancet D&E 2025–26); SLIMMER (n=664, Lancet D&E / ADA 2025) |
The Core Innovation: Biased Agonism
Traditional GLP-1RAs (semaglutide, liraglutide) trigger two pathways simultaneously:
- Gαs → cAMP (therapeutic: insulin secretion, satiety, fat loss) ✅
- β-arrestin recruitment → receptor internalization (desensitization/tachyphylaxis) ❌
Ecnoglutide selectively hyperactivates pathway 1 while nearly eliminating pathway 2:
| Parameter | Ecnoglutide | Semaglutide |
|---|---|---|
| cAMP potency (EC50) | 0.018 nM | 0.012 nM |
| β-arrestin recruitment (Emax) | 60% | 100% |
| Receptor internalization (EC50) | >10 µM | 0.093 µM |
Result: Receptors stay on the cell surface → continuous, uninterrupted signaling → no efficacy plateau.
Clinical Trial Data
EECOH-1 (Monotherapy T2DM, n=211, 52 weeks — Nature Comms Jan 2026)
| Arm | HbA1c reduction | Normoglycemia | Weight change |
|---|---|---|---|
| Placebo | −0.87% | 0% | −2.02% |
| 0.6 mg | −1.96%* | 10.1% | −4.51%* |
| 1.2 mg | −2.43%* | 35.2% | −4.74%* |
EECOH-2 (vs. Dulaglutide 1.5mg, n=623, 52 weeks — Lancet D&E 2025)
Ecnoglutide 1.2 mg: −1.91% HbA1c vs dulaglutide −1.65% (superior, p<0.05); also superior on weight loss and fasting triglycerides.
SLIMMER (Obesity, n=664, 48 weeks — Lancet D&E / ADA 2025)
| Dose | Mean weight loss | ≥10% loss | ≥20% loss |
|---|---|---|---|
| Placebo | −0.3% | 4.8% | 0% |
| 1.2 mg | −9.9% | 51.2% | 9.0% |
| 1.8 mg | −13.3% | 75.9% | N/A |
| 2.4 mg | −15.4% | 79.6% | 28.0% |
Defining differentiator: No plateau at week 48 — patients still losing at trial end.
vs. Semaglutide 2.4 mg: STEP-7 (Chinese cohort) = 12.1% weight loss. Ecnoglutide = 15.4% — demonstrably superior in same demographic.
vs. Tirzepatide 15 mg: SURMOUNT-CN (Chinese cohort): tirzepatide = 15.8% / 15.1% placebo-adjusted. Ecnoglutide = 15.4% / 15.1% placebo-adjusted — essentially equivalent despite single receptor.
Liver fat (MASLD subgroup): 53.1% hepatic fat reduction at week 40 (MRI-PDFF).
The Lean Mass Problem
Same problem as all GLP-1RAs: 25–40% of weight lost may be muscle. This is the critical integration issue.
Solutions:
- High-protein diet + resistance training (foundational)
- XW4475 (UCN2): pharmacological muscle preservation via myostatin/activin pathway; natural complement — ecnoglutide drives fat loss, XW4475 prevents/reverses muscle loss. Co-formulation likely (Sciwind already studying combo)
- SLU-PP-332: ERR agonist drives mitochondrial biogenesis + oxidative fiber shift; protects lean mass during deficit
- BPC-157: angiogenesis + tissue repair supports muscle preservation during deficit
Pipeline
- Oral ecnoglutide (XW004 / VRB-101): Phase 1 (Australia): 6.76% weight loss in 6 weeks. Phase 2b EVOLVE-2 (NCT07281937) readout late 2026–mid-2027.
- OSA indication: Phase 3 (NCT07387094).
Links
- XW4475 — muscle preservation pairing (primary integration concern)
- SLU-PP-332 — lean mass protection, complementary ERR axis
- BPC-157 — tissue repair support during deficit
- Retatrutide — GLP-1/GIP/glucagon triple; significant overlap at GLP-1R; stacking may be redundant unless adding XW4475
- GLP-1 GIP Glucagon — mechanistic background; clinical pharmacology comparison table
- Peptides MOC — peptide/compound hub index